6990.HK in “China Becomes Pharma's Global R&D Engine”
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Its antibody-drug conjugate portfolio makes it a key supplier of sought-after oncology assets to multinational pharma.
6990.HK impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to 6990.HK’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading 6990.HK impact map…
Price history, marked with story events
Aug 31, 2026 – Sep 29, 2026 · 22 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — Its antibody-drug conjugate portfolio makes it a key supplier of sought-after oncology assets to multinational pharma.
Read the full China Becomes Pharma's Global R&D Engine story